Arno Therapeutics (United States)

Recent papers from Arno Therapeutics (United States)

1. Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D InhibitorCancer Discovery · 2026
2. The Potential Role of NOD2/CARD15 Genotype as a Prognostic Indicator for Bone Marrow Transplantation Outcomes in Patients With Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: A Systematic ReviewCureus · 2024
3. The Benefits of Integrative Medicine for Pain Management in Oncology: A Narrative Review of the Current EvidenceCureus · 2023
4. Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane AntigenCureus · 2023
5. Data from A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies2023
6. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersPLoS ONE · 2018
7. The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prionsScientific Reports · 2017
8. Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypesJournal of Antimicrobial Chemotherapy · 2017
9. AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus ReplicationJournal of Cellular Physiology · 2016
10. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone functionOncotarget · 2016
11. A Phase I Study of 7- t -Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid MalignanciesClinical Cancer Research · 2010
12. Improving the quality of antibiotic prescription patterns in general practiceThe Medical Journal of Australia · 1994